On 29 January 2018, Sanofi launched a public tender offer on Ablynx at a price per share of €45.
 
Ablynx is a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments for a broad range of therapeutic indications with an unmet medical need. 
 
Eubelius has acted as counsel to Ablynx since inception in 2001, assisted the company with its Euronext Brussels IPO as well with its recent successful Nasdaq IPO, and now acts as its lead legal counsel for the tender offer.
 
The team members involved in the transaction are Lars Van Bever, Matthias Wauters, Joris De Wolf and Eva Milants.